Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colony stimulating factor 1 (CSF1), also known as macrophage colony-stimulating factor (M-CSF), is a cytokine and hematopoietic growth factor that plays an essential role in the regulation of survival, proliferation, and differentiation of hematopoietic precursor cells, particularly mononuclear phagocytes such as macrophages and monocytes. It binds to the colony stimulating factor 1 receptor (CSF1R) to activate downstream signaling pathways. Recombinant and purified forms of CSF1, including lanimostim, mirimostim, and cilmostim, have been developed for clinical use. Mirimostim (marketed as Leukoprol) is approved in Japan for the treatment of neutropenia and to facilitate hematopoietic recovery after bone marrow transplantation or intensive chemotherapy. Other forms have been investigated for indications such as hypercholesterolemia and infectious diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colony stimulating factor 1.